- Home
- WNEB vs ACHV Comparison
WNEB vs ACHV Comparison
Compare WNEB & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- ACHV
- Stock Information
- Founded
- WNEB 1853
- ACHV N/A
- Country
- WNEB United States
- ACHV Canada
- Employees
- WNEB N/A
- ACHV N/A
- Industry
- WNEB Savings Institutions
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- WNEB Finance
- ACHV Health Care
- Exchange
- WNEB Nasdaq
- ACHV Nasdaq
- Market Cap
- WNEB 165.5M
- ACHV 159.0M
- IPO Year
- WNEB N/A
- ACHV N/A
- Fundamental
- Price
- WNEB $8.90
- ACHV $4.52
- Analyst Decision
- WNEB Hold
- ACHV Strong Buy
- Analyst Count
- WNEB 4
- ACHV 3
- Target Price
- WNEB $8.50
- ACHV $14.00
- AVG Volume (30 Days)
- WNEB 40.7K
- ACHV 87.9K
- Earning Date
- WNEB 10-22-2024
- ACHV 11-07-2024
- Dividend Yield
- WNEB 3.21%
- ACHV N/A
- EPS Growth
- WNEB N/A
- ACHV N/A
- EPS
- WNEB 0.63
- ACHV N/A
- Revenue
- WNEB $74,435,000.00
- ACHV N/A
- Revenue This Year
- WNEB N/A
- ACHV N/A
- Revenue Next Year
- WNEB $5.16
- ACHV N/A
- P/E Ratio
- WNEB $13.77
- ACHV N/A
- Revenue Growth
- WNEB N/A
- ACHV N/A
- 52 Week Low
- WNEB $6.00
- ACHV $3.03
- 52 Week High
- WNEB $9.25
- ACHV $5.98
- Technical
- Relative Strength Index (RSI)
- WNEB 59.33
- ACHV 50.71
- Support Level
- WNEB $8.45
- ACHV $4.23
- Resistance Level
- WNEB $8.99
- ACHV $4.33
- Average True Range (ATR)
- WNEB 0.18
- ACHV 0.15
- MACD
- WNEB -0.05
- ACHV 0.02
- Stochastic Oscillator
- WNEB 37.04
- ACHV 53.13
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.